Abstract
Background Abnormal gait will alter lower extremity joint mechanics load-bearing patterns, accelerate the osteoarticular disease process, trigger new oste-oarticular complications, and bring about multiple mobility impairments; scientific pain management strategies can help with walking training and rehabilitation exercises. However, studies to date on the relationship between localized musculoskeletal pain and gait abnormalities have not reached definitive conclusions.
Purpose To investigate the bidirectional causal relationship between localized musculoskeletal pain and gait abnormalities.
Methods The independent single nucleotide polymorphism (SNP) loci strongly associated with pain were extracted as instrumental variables (IVs) from Genome-wide association study (GWAS) data of localized musculoskeletal pain according to preset thresholds, and Inverse-variance weighted (IVW) method was used to assess the association between pain-related phenotypes and gait abnormalities; the Cochran Q test was used to assess the heterogeneity of the SNPs.
Results Low back pain (OR=1.53, 95%CI=1.058∼2.219, P=0.023) and hip pain (OR=1.55, 95%CI=1.067∼2.252, P=0.021) were significantly genetically predisposed to gait abnormalities, but knee pain (OR=2.15, 95%CI=0.234∼19.789, P=0.498) was not significantly genetically susceptible to gait abnormalities. None of the results of the reverse MR analysis supported reverse causality. The Cochran Q test showed no heterogeneity among the SNPs.
Conclusions This study suggests a robust correlation, gait abnormalities are related to low back pain and hip pain. Our findings contribute to a deeper comprehension of the intricate interplay between localized musculoskeletal pain and gait abnormalities, emphasizing the importance of employing tailored strategies to alleviate localized musculoskeletal pain.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Yes
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
In the corresponding original Genome-wide association study (GWAS), all participants provided written informed consent. So the submission does not require an additional ethics statement.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability Statement
All data generated or analyzed during this study are included in this published article and its supplementary information files.
